New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT04250155
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take part in this early-phase trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center - PPDS
Seoul, 05505, South Korea
-
City of Hope Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
-
Clinica Universidad de Navarra-Madrid
Madrid, 28027, Spain
-
Clinica Universitaria de Navarra
Pamplona, Navarre, 31008, Spain
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, 20133, Italy
-
GasthuisZusters Antwerpen
Wilrijk, Antwerp, 2610, Belgium
-
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, North Holland, 1066 CX, Netherlands
-
Honor Health Research Institute
Scottsdale, Arizona, 85258, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital de Clinicas de Porto Alegre HCPA PPDS
Porto Alegre, Rio Grande do Sul, 90560-030, Brazil
-
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, 01246-000, Brazil
-
Istituto Clinico Humanitas
Rozzano, Lombardy, 20089, Italy
-
Istituto Europeo Di Oncologia
Milan, Lombardy, 20141, Italy
-
Parkville Cancer Clinical Trial Unit (PCCTU)
Melbourne, Victoria, 3000, Australia
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Samsung Medical Center - PPDS
Seoul, 06351, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital Yonsei University Health System - PPDS
Seoul, 03722, South Korea
-
Stanford Health Centre - Palo Alto
Palo Alto, California, 94304, United States
-
Universitair Medisch Centrum Groningen
Groningen, 9713 GZ, Netherlands
-
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158-2545, United States
-
Yale University
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?